Maternal RSVpreF Vaccine Reduces Infant Hospitalizations

A study led by the University of Pittsburgh and University of Pittsburgh Medical Center, funded by Pfizer and the United States — National Institutes of Health, and published in JAMA Network Open, has provided compelling real-world evidence that maternal vaccination with the RSVpreF vaccine significantly reduces RSV-associated hospitalizations in infants. The study, led by Anne-Marie Rick, found that the vaccine, approved by the United States — Food and Drug Administration in 2023, is approximately 68% effective against RSV-associated acute respiratory illness hospitalization and 69% effective against lower respiratory tract disease hospitalization in infants 90 days or younger. This breakthrough offers a new preventive strategy against RSV, a leading cause of infant hospitalizations in the United States.